News
Eli Lilly stock falls 14% after new obesity drug underwhelms in clinical trial. Analysts maintain Buy rating, citing strong ...
Benzinga on MSN31m
Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market- What's Going On?Shares of Novo Nordisk climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly’s Phase 3 ATTAIN-1 ...
InvestorsHub on MSN53m
Novo Nordisk Shares Climb for Second Day as Lilly’s Obesity Pill Falls Short of Wegovy in TrialShares of Novo Nordisk (NYSE:NVO), traded in Copenhagen, rose over 5% on Friday, extending gains from the previous session.
Eli Lilly, the manufacturer of a new weight-loss pill (an alternative to popular weight-loss jabs), says the drug could be ...
Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...
This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback